GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Net Income (Continuing Operations)

Biotechnology Assets (XMAD:BST) Net Income (Continuing Operations) : €1.57 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Biotechnology Assets's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was €-1.38 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was €1.57 Mil.

Biotechnology Assets Net Income (Continuing Operations) Historical Data

The historical data trend for Biotechnology Assets's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets Net Income (Continuing Operations) Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.01 -1.71 -3.01 -1.94 1.57

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -1.50 -0.45 2.95 -1.38

Biotechnology Assets Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets  (XMAD:BST) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Biotechnology Assets Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotechnology Assets (XMAD:BST) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Net Income (Continuing Operations)
Comparable Companies
XMAD:ORY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX LEGN
Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Website
https://www.biatgroup.com
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.